Plus Therapeutics (PSTV) has disclosed a new risk, in the Debt & Financing category.
Plus Therapeutics faces critical financial challenges as evidenced by a stockholders’ deficit of $480.5 million and insufficient liquidity to sustain operations beyond the next year. Their situation is precarious, given a history of losses and negative cash flows, with ongoing viability hinging on securing additional financing. Without fresh capital, the company may have to drastically scale back operations, potentially losing rights to key intellectual properties or halting clinical trials, thereby jeopardizing its future prospects.
Overall, Wall Street has a Moderate Buy consensus rating on PSTV stock based on 1 Buy.
To learn more about Plus Therapeutics’ risk factors, click here.
